Is Neuronetics Stock a Good Investment?
Neuronetics Investment Advice | STIM |
- Examine Neuronetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neuronetics' leadership team and their track record. Good management can help Neuronetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Neuronetics' business and its evolving consumer preferences.
- Compare Neuronetics' performance and market position to its competitors. Analyze how Neuronetics is positioned in terms of product offerings, innovation, and market share.
- Check if Neuronetics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neuronetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neuronetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neuronetics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Solid | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neuronetics Stock
Researching Neuronetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.37. Neuronetics had not issued any dividends in recent years.
To determine if Neuronetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuronetics' research are outlined below:
| Neuronetics is way too risky over 90 days horizon | |
| Neuronetics appears to be risky and price may revert if volatility continues | |
| Neuronetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 74.89 M. Net Loss for the year was (43.2 M) with profit before overhead, payroll, taxes, and interest of 54.16 M. | |
| Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71. | |
| Neuronetics has a poor financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Wall Street Analysts Think Neuronetics Could Surge 34.98 percent Read This Before Placing a Bet |
Neuronetics Quarterly Long Term Debt |
|
Neuronetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuronetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuronetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Neuronetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neuronetics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2021-08-03 | 2021-06-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2021-03-02 | 2020-12-31 | -0.24 | -0.19 | 0.05 | 20 | ||
2024-08-12 | 2024-06-30 | -0.27 | -0.33 | -0.06 | 22 | ||
2019-11-05 | 2019-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2024-03-05 | 2023-12-31 | -0.26 | -0.19 | 0.07 | 26 | ||
2023-03-07 | 2022-12-31 | -0.38 | -0.3 | 0.08 | 21 | ||
2020-11-02 | 2020-09-30 | -0.28 | -0.18 | 0.1 | 35 |
Know Neuronetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuronetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuronetics backward and forwards among themselves. Neuronetics' institutional investor refers to the entity that pools money to purchase Neuronetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Accurate Wealth Management, Llc | 2024-12-31 | 78.9 K | Gamco Investors, Inc. Et Al | 2024-12-31 | 77.9 K | Bank Of America Corp | 2024-12-31 | 67.2 K | Northern Trust Corp | 2024-12-31 | 56.7 K | Jpmorgan Chase & Co | 2024-12-31 | 54.9 K | Fmr Inc | 2024-12-31 | 46.7 K | David J Yvars Group | 2024-12-31 | 46.3 K | Bridgeway Capital Management, Llc | 2024-12-31 | 45.2 K | Gabelli Funds Llc | 2024-12-31 | 38 K | Masters Capital Management Llc | 2024-12-31 | 1.5 M | Balyasny Asset Management Llc | 2024-12-31 | 1.5 M |
Neuronetics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 325.05 M.Market Cap |
|
Neuronetics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (1.02) | (1.07) |
Determining Neuronetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Neuronetics is a good buy. For example, gross profit margin measures Neuronetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuronetics' profitability and make more informed investment decisions.
Evaluate Neuronetics' management efficiency
Neuronetics has return on total asset (ROA) of (0.1707) % which means that it has lost $0.1707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4819) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Neuronetics' Net Tangible Assets are very stable compared to the past year. As of the 21st of March 2025, Other Current Assets is likely to grow to about 8.8 M, while Non Current Assets Total are likely to drop about 13.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.07 | 1.13 | |
| Tangible Book Value Per Share | 0.94 | 0.99 | |
| Enterprise Value Over EBITDA | (4.34) | (4.56) | |
| Price Book Value Ratio | 2.19 | 1.94 | |
| Price Fair Value | 2.19 | 1.94 | |
| Enterprise Value Multiple | (4.34) | (4.56) | |
| Enterprise Value | 828.8 K | 787.4 K |
The operational strategies employed by Neuronetics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 2.072 |
Basic technical analysis of Neuronetics Stock
As of the 21st of March, Neuronetics secures the Downside Deviation of 7.34, mean deviation of 6.97, and Risk Adjusted Performance of 0.2561. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuronetics, as well as the relationship between them. Please verify Neuronetics jensen alpha and downside variance to decide if Neuronetics is priced some-what accurately, providing market reflects its recent price of 4.94 per share. Given that Neuronetics has jensen alpha of 2.65, we recommend you to check Neuronetics's last-minute market performance to make sure the company can sustain itself at a future point.Neuronetics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuronetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuronetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuronetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuronetics' Outstanding Corporate Bonds
Neuronetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuronetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuronetics bonds can be classified according to their maturity, which is the date when Neuronetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Neuronetics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neuronetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.2561 | |||
| Market Risk Adjusted Performance | 2.84 | |||
| Mean Deviation | 6.97 | |||
| Semi Deviation | 5.84 | |||
| Downside Deviation | 7.34 | |||
| Coefficient Of Variation | 359.03 | |||
| Standard Deviation | 9.29 | |||
| Variance | 86.33 | |||
| Information Ratio | 0.2855 | |||
| Jensen Alpha | 2.65 | |||
| Total Risk Alpha | 3.36 | |||
| Sortino Ratio | 0.3612 | |||
| Treynor Ratio | 2.83 | |||
| Maximum Drawdown | 51.44 | |||
| Value At Risk | (10.80) | |||
| Potential Upside | 18.78 | |||
| Downside Variance | 53.93 | |||
| Semi Variance | 34.11 | |||
| Expected Short fall | (8.42) | |||
| Skewness | 0.8918 | |||
| Kurtosis | 2.09 |
| Risk Adjusted Performance | 0.2561 | |||
| Market Risk Adjusted Performance | 2.84 | |||
| Mean Deviation | 6.97 | |||
| Semi Deviation | 5.84 | |||
| Downside Deviation | 7.34 | |||
| Coefficient Of Variation | 359.03 | |||
| Standard Deviation | 9.29 | |||
| Variance | 86.33 | |||
| Information Ratio | 0.2855 | |||
| Jensen Alpha | 2.65 | |||
| Total Risk Alpha | 3.36 | |||
| Sortino Ratio | 0.3612 | |||
| Treynor Ratio | 2.83 | |||
| Maximum Drawdown | 51.44 | |||
| Value At Risk | (10.80) | |||
| Potential Upside | 18.78 | |||
| Downside Variance | 53.93 | |||
| Semi Variance | 34.11 | |||
| Expected Short fall | (8.42) | |||
| Skewness | 0.8918 | |||
| Kurtosis | 2.09 |
Consider Neuronetics' intraday indicators
Neuronetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuronetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 24717.45 | |||
| Daily Balance Of Power | (0.25) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 4.99 | |||
| Day Typical Price | 4.97 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.07) | |||
| Relative Strength Index | 56.51 |
Neuronetics Corporate Filings
| 13th of March 2025 Other Reports | ViewVerify | |
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of February 2025 Other Reports | ViewVerify |
Neuronetics Stock media impact
Far too much social signal, news, headlines, and media speculation about Neuronetics that are available to investors today. That information is available publicly through Neuronetics media outlets and privately through word of mouth or via Neuronetics internal channels. However, regardless of the origin, that massive amount of Neuronetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuronetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuronetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuronetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuronetics alpha.
Neuronetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neuronetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuronetics Historical Investor Sentiment
Investor biases related to Neuronetics' public news can be used to forecast risks associated with an investment in Neuronetics. The trend in average sentiment can be used to explain how an investor holding Neuronetics can time the market purely based on public headlines and social activities around Neuronetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuronetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuronetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuronetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuronetics.
Neuronetics Corporate Management
| Andrew JD | GC, VP | Profile | |
| Rusty Page | Senior Quality | Profile | |
| Lisa MetznerRosas | Senior Officer | Profile | |
| Andrew Macan | Gen VP | Profile | |
| Claire Sears | VP Marketing | Profile | |
| Rick Grubbs | Senior Accounts | Profile | |
| Cory Anderson | Senior Clinical | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Revenue Per Share | Quarterly Revenue Growth 0.107 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neuronetics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.